JP2018517736A - 炎症性疾患又は病態を治療する組成物及び方法 - Google Patents

炎症性疾患又は病態を治療する組成物及び方法 Download PDF

Info

Publication number
JP2018517736A
JP2018517736A JP2017565134A JP2017565134A JP2018517736A JP 2018517736 A JP2018517736 A JP 2018517736A JP 2017565134 A JP2017565134 A JP 2017565134A JP 2017565134 A JP2017565134 A JP 2017565134A JP 2018517736 A JP2018517736 A JP 2018517736A
Authority
JP
Japan
Prior art keywords
nsaid
cocreatate
less
subject
cocreated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017565134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517736A5 (enExample
Inventor
ラファエル ジェイ． マンニーノ
ラファエル ジェイ． マンニーノ
ルーイン ルー
ルーイン ルー
Original Assignee
マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド, マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド filed Critical マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド
Publication of JP2018517736A publication Critical patent/JP2018517736A/ja
Publication of JP2018517736A5 publication Critical patent/JP2018517736A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017565134A 2015-06-18 2016-06-17 炎症性疾患又は病態を治療する組成物及び方法 Withdrawn JP2018517736A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562181347P 2015-06-18 2015-06-18
US62/181,347 2015-06-18
US201662289025P 2016-01-29 2016-01-29
US62/289,025 2016-01-29
US201662347014P 2016-06-07 2016-06-07
US62/347,014 2016-06-07
PCT/US2016/038084 WO2016205654A1 (en) 2015-06-18 2016-06-17 Compositions and methods for treating inflammatory disease or conditions

Publications (2)

Publication Number Publication Date
JP2018517736A true JP2018517736A (ja) 2018-07-05
JP2018517736A5 JP2018517736A5 (enExample) 2019-06-27

Family

ID=57546667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565134A Withdrawn JP2018517736A (ja) 2015-06-18 2016-06-17 炎症性疾患又は病態を治療する組成物及び方法

Country Status (8)

Country Link
US (1) US20180185308A1 (enExample)
EP (1) EP3310338A4 (enExample)
JP (1) JP2018517736A (enExample)
KR (1) KR20180014790A (enExample)
CN (1) CN107920991A (enExample)
AU (1) AU2016280276A1 (enExample)
CA (1) CA2987798A1 (enExample)
WO (1) WO2016205654A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004104A (ko) 2015-03-03 2018-01-10 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759057B1 (en) * 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2001052817A2 (en) * 2000-01-24 2001-07-26 Biodelivery Sciences, Inc. Cochleate formulations and their use for delivering biologically relevant molecules
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
CA2504329C (en) * 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
JP6347743B2 (ja) * 2011-05-05 2018-06-27 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド コクリエート組成物およびその製造および使用方法
MX361155B (es) * 2012-07-30 2018-11-28 Matinas Biopharma Nanotechnologies Inc Cocleatos hechos con fosfatidilserina de soja.

Also Published As

Publication number Publication date
US20180185308A1 (en) 2018-07-05
CA2987798A1 (en) 2016-12-22
AU2016280276A1 (en) 2017-12-07
EP3310338A1 (en) 2018-04-25
CN107920991A (zh) 2018-04-17
EP3310338A4 (en) 2018-12-26
WO2016205654A1 (en) 2016-12-22
KR20180014790A (ko) 2018-02-09

Similar Documents

Publication Publication Date Title
JP6923206B2 (ja) マイコバクテリア感染症及び肺疾患を治療するための組成物及び方法
JP6609286B2 (ja) ヒトにおける炎症性障害の治療用リポソームコルチコステロイド
CN106456662A (zh) 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
JP6770524B2 (ja) コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法
US20150352039A1 (en) Sonosensitive liposome, pharmaceutical composition including the same, and method of delivering active agent to subject using the sonosensitive liposome
JP2017048229A (ja) 制御放出粘膜付着システム
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP2018517736A (ja) 炎症性疾患又は病態を治療する組成物及び方法
TWI857961B (zh) 減少關節內類固醇的併發症之方法
EP1694298A2 (en) Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same
RU2806023C2 (ru) Способы уменьшения осложнений от внутрисуставного стероида
AU2019361980B2 (en) Method and device of treating chronic kidney disease-associated pruritus
US20200281950A1 (en) Liposomes for treatment of an autoimmune disease
NZ625022B2 (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190530